Clinical Trials

42 enrolled

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT03375307 2026-03-18

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

60 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05411094 2026-03-18

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

18 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05554328 2026-03-18

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

165 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT04585958 2026-03-17

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Other hematologic neoplasm

55 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03486873 2026-03-16

MK-3475-587

Phase 3 Recruiting

3,500 enrolled

Hematologic Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06353386 2026-03-13

MK-5684-01A

Phase 1/2 Recruiting

220 enrolled

Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT07018622 2026-03-11

DAPA-ARMOR

46 enrolled

Other solid neoplasm

Solid Tumors

NCT07460180 2026-03-10

PROOV

Phase 1/2 Recruiting

55 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05188508 2026-03-06

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

57 enrolled

CNS

Glioma

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

60 enrolled

Breast

Breast Neoplasms

NCT07371104 2026-03-05

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

40 enrolled

Neoplasms, Ovarian Neoplasms

NCT03297606 2026-03-04

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

78 enrolled

CNS

Glioblastoma

NCT07024784 2026-03-04

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

377 enrolled

Phase EARLY_PHASE1 Recruiting

Fallopian Tube Neoplasms, Neoplasms

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

90 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06915025 2026-02-27

OVATION-3

Phase 3 Recruiting

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer